Navigation Links
ProImmune Launches New MHC-Peptide Binding Assay for Class II HLA Alleles
Date:9/24/2007

OXFORD, England, September 24 /PRNewswire/ -- ProImmune Ltd., a leading provider of quality research reagents for monitoring the immune system and services for antigen discovery, has announced the launch of its new MHC-peptide binding assay for Class II HLA alleles, adding to the series of discovery services for Class I HLA already available from the Company.

The Class II REVEAL(TM) binding assay for HLA alleles DR1-4, is a powerful cell-free in vitro assay that can rapidly predict T-cell antigens in any protein sequence. It is widely applicable across many disease areas such as cancer, infectious diseases, autoimmunity and in transplantation, and is ideally suited to therapeutic programmes with time pressures, such as the development of vaccines for emerging diseases.

Unlike traditional methods for discovering T-cell antigens, such as functional cellular assays, the Class II REVEAL(TM) assay does not use patient samples, and uniquely determines the HLA restriction of each antigen in a single step. Class II REVEAL(TM) therefore offers a significant timesaving advantage, and reduces the overall cost and risk of discovery projects.

The launch of Class II REVEAL(TM) follows ProImmune's recent extension of its range of MHC Class II Ultimer(TM) staining reagents with alleles DR2 and DR3 to cover HLA DR1 to 4. Class II Ultimers(TM) can be used to validate antigens discovered with REVEAL(TM), and in monitoring and phenotyping of targeted immune responses.

Dr. Nikolai Schwabe, CEO of ProImmune, said "Class II REVEAL(TM) helps to overcome a significant barrier in understanding key helper T-cell immune responses in detail, and to harness such responses in the design of highly targeted therapies across a very wide range of diseases".

ProImmune Ltd is a private biotechnology company based in Oxford, UK, that specializes in providing antigen discovery services and research reagents for monitoring the immune system. ProImmune has a wide range of customers from pharmaceutical and biotechnology companies, to clinical and academic research institutes throughout the world. The Company, founded in November 1999, has secured R&D funding from several DTI Smart, EUREKA and EU Framework VI project grants and has been profitable since its inception. ProImmune owns a portfolio of international patents and patent applications protecting its core products and technologies. The Company also has offices in the USA. http://www.proimmune.com

Media enquiries:

Gemma Price

Northbank Communications

Tel: +44-(0)-20-7268-3002

Email: g.price@northbankcommunications.com


'/>"/>
SOURCE ProImmune Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Merge launches diagnostic mammography workstation in Europe
2. Einstein Wireless launches cellular alert system
3. Logistics Health launches compliance management tool
4. UW-Madison launches new high-speed research network
5. UWM launches research foundation
6. TeraMedica launches information manager
7. GE Healthcare launches hybrid electronic record
8. Cedara launches new version of DICOM toolkit
9. Merge launches Spanish version of imaging tool
10. Doyle launches 2025 alternative energy plan
11. Jellyfish launches comparative shopping website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... of a complex biological network, a depiction of a system of linkages and ... Dmitry Korkin, PhD, associate professor of computer science at Worcester Polytechnic Institute (WPI) ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, will ... analytical testing are being attributed to new regulatory requirements for all new drug ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit ... 7th and 8th June 2018 in San Francisco, CA. The Summit brings together current ... several distinguished CEOs, board directors and government officials from around the world to address ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published in ... and fresh in vitro fertilization (IVF) transfer cycles. The multi-center matched ... , After comparing the results from the fresh and frozen transfer cohorts, the ...
Breaking Biology Technology:
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/24/2017)... MILAN , March 24, 2017 The Controller ... Deputy Controller Mr. Abdulla Algeen have received the prestigious international ... Continue Reading ... ... small picture) and Deputy Controller Abdulla Algeen (small picture on the right) ...
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Vehicle Anti-Theft ... 8.8% over the next decade to reach approximately $14.21 billion by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):